Beam Therapeutics Inc. (BEAM) News

Beam Therapeutics Inc. (BEAM): $40.40

-2.69 (-6.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BEAM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter BEAM News Items

BEAM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BEAM News Highlights

  • BEAM's 30 day story count now stands at 5.
  • Over the past 14 days, the trend for BEAM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • BASE, ARCH and PEAK are the most mentioned tickers in articles about BEAM.

Latest BEAM News From Around the Web

Below are the latest news stories about Beam Therapeutics Inc that investors may wish to consider to help them evaluate BEAM as an investment opportunity.

10 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming

In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […]

Yahoo | February 23, 2022

Top 10 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group

In this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green’s Redmile Group. If you want to skip our detailed analysis of Green’s history, investment philosophy performance, you can go directly to the Top 5 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group. Jeremy Green is the […]

Yahoo | February 17, 2022

Beam Therapeutics Inc. (NASDAQ: BEAM) Has Fallen -114.43% From Its Highs, What Comes Next?

Beam Therapeutics Inc. (NASDAQ:BEAM)’s traded shares stood at 1.13 million during the last session. At the close of trading, the stock’s price was $64.60, to imply a decrease of -5.56% or -$3.8 in intraday trading. The BEAM share’s 52-week high remains $138.52, putting it -114.43% down since that peak but still an impressive 12.79% since … Beam Therapeutics Inc. (NASDAQ: BEAM) Has Fallen -114.43% From Its Highs, What Comes Next? Read More »

Marketing Sentinel | February 11, 2022

Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET.

GlobeNewswire | February 9, 2022

Why Pfizer's Deal With Beam Therapeutics Is a Smart Move

Pfizer (NYSE: PFE) recently announced a collaboration with Beam Therapeutics (NASDAQ: BEAM) to develop gene-editing therapies targeting rare genetic diseases. In this Motley Fool Live video, recorded on Jan. 12., Fool contributors Keith Speights and Brian Orelli discuss why Pfizer's deal with Beam appears to be a smart move. Keith Speights: We mentioned this on Monday I believe, that Pfizer had announced a collaboration with Beam Therapeutics to develop therapies targeting rare genetic diseases.

Yahoo | January 23, 2022

Are Illumina and Beam Therapeutics the Healthcare Industry's Rising Stars?

In this Motley Fool Live video recorded on Jan. 12, 2022, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not the two companies are rising stars in healthcare. Keith Speights: Illumina, which we've talked about, and Beam Therapeutics, she says, "Are they rising stars, and what about other CRISPR stocks?" Are Illumina and Beam rising stars, Brian?

Yahoo | January 22, 2022

Why Is Pfizer Teaming Up With Acuitas Therapeutics?

Pfizer (NYSE: PFE) is putting some of its growing cash stockpile to use. The big drugmaker recently announced a collaboration with Acuitas Therapeutics. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss why Pfizer is teaming up with Acuitas.

Yahoo | January 22, 2022

Pfizer''s Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy

No summary available.

Seeking Alpha | January 19, 2022

The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo

Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.

Yahoo | January 17, 2022

Is Beam Therapeutics a Good Stock to Buy Now?

Beam Therapeutics (NASDAQ: BEAM) recently signed a major research deal with Pfizer (NYSE: PFE) that could be worth up to $1.35 billion, and hardly anyone seemed to notice. Instead of surging higher in response to the Pfizer deal, Beam Therapeutics stock actually fell nearly 2% on the day of the announcement. Over the past few years, Pfizer has watched its peers experiment with CRISPR-based gene editing techniques without making any significant investments.

Yahoo | January 16, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.444 seconds.